China approves Pfizer GLP-1 drug for weight management [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
adults, the US drugmaker ?said on WeChat on Friday, boosting competition in a market ?analysts expect to be worth billions in coming years.The injection belongs to the class of GLP-1 receptor agonist drugs sold locally by drugmakers such as Novo Nordisk, ?Eli Lilly, and ?Innovent Biologics. "This marks a breakthrough in field of weight management," Sciwind Biosciences, from which ?Pfizer licensed mainland China commercialisation rights in February, said on its website. Sales of Novo's Wegovy on Alibaba's ?Tmall e-commerce ?platform and JD.com were ?260 million yuan ($38 million) ?in 2025, against 416 million ($61 million) for Innovent's Xinermei, investment bank Jefferies said in a note. In February, Pfizer licensed the mainland China commercialisation rights for Xianweiying, also known as ecnoglutide, from Sciwind, based in the ?eastern city of Hangzhou. That deal was "an ?important first step to advance ?Pfizer's global strategy ?in the metabolic field in China", Sciwind ?sa
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Zealand's stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics' [CNBC]CNBC
- Caliber Launches U.S. Expert Advisory Council to Advance Real-Time Stakeholder Intelligence [Yahoo! Finance]Yahoo! Finance
- Lexicon Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVOPR Newswire
- Harbor International Compounders Fund Q4 2025 Commentary [Seeking Alpha]Seeking Alpha
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/2/26 - Form 6-K
- 3/2/26 - Form 6-K
- 2/23/26 - Form 6-K
- NVO's page on the SEC website